Amgen enters springboard year with new product portfolio
Statements (12)
- Bullish
Amgen is likely to see its stock price rise following its positive results for the Sjogren's treatment.
- Bullish
Amgen reported double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE during Q2.
- Bullish
Amgen reported higher revenue and growth across its portfolio of medicines
- Bullish
Amgen raised its full-year outlook following strong second-quarter results.
- Bullish
Amgen reported second-quarter revenue of $2.38 billion, exceeding expectations.
- Bullish
Amgen expects full-year revenue between $38.2 billion and $39.4 billion
- Bullish
Amgen is likely to see its stock price rise due to the company's improved outlook on drug sales and decision to halt development of a potential obesity treatment.
- Neutral
Amgen is halting development of a potential obesity treatment in phase 1 study
- Bullish
Amgen Inc. reported second-quarter revenue of $10.1 billion for fiscal 2026, up 10% on an annual level.
- Bullish
Amgen is likely to see its stock price rise due to its Q2 revenue exceeding annual projections.
- Bullish
Amgen Inc. reported second-quarter revenue of $10.1 billion for fiscal 2026, exceeding annual projections.
- Bullish
Amgen is likely to see increased demand for its cardiovascular drug Repatha following the positive CHMP opinion, as the approval supports broader use prior to a first heart attack or stroke.